Physician profile
Sharon L Lytle
NPI 1679762686
$744.38
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.69 · 2022: $254 · 2023: $228 · 2024: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.55 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $102.92 | 2022-2024 | |
| Exeltis, USA INC. | $73.83 | 2022-2024 | Slynd |
| Baxter Healthcare | $47.98 | 2024 | Perclot, Floseal |
| Hologic Sales and Service, LLC | $38.48 | 2022-2024 | Aptima |
| Avion Pharmaceuticals | $35.78 | 2023 | Balcoltra |
| Therapeuticsmd, INC. | $32.84 | 2022 | |
| Biogen, INC. | $28.30 | 2024 | Zurzuvae |
| Coopersurgical, INC. | $27.97 | 2024 | Paragard T 380a |
| Astellas Pharma US INC | $18.67 | 2024 | Veozah |
| Pfizer INC. | $18.48 | 2024 | |
| Amgen INC. | $17.69 | 2021 | |
| Sage Therapeutics, LLC | $17.51 | 2023 | |
| Mylan Pharmaceuticals INC. | $17.17 | 2022 | |
| Evofem Biosciences, INC. | $17.01 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $15.66 | 2023 | |
| Smith+Nephew, INC. | $14.54 | 2024 | Pico 7, Acticoat 4" X 4", Pico 14 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lytle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.